<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02649478</url>
  </required_header>
  <id_info>
    <org_study_id>FLSA-P100/50-PVCL-1</org_study_id>
    <nct_id>NCT02649478</nct_id>
  </id_info>
  <brief_title>Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate</brief_title>
  <official_title>A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roxane Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vectura Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>West-Ward Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of
      Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder
      Compared with Advair Diskus® 100/50 in Subjects with Asthma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to evaluate the clinical bioequivalence of generic
      fluticasone propionate 100 µg and salmeterol xinafoate 50 µg inhalation powder (test) to
      Advair Diskus (&quot;Advair&quot;) 100/50 (reference) for the treatment of asthma.

      The secondary objectives of the study are:

        -  To demonstrate statistical superiority of generic fluticasone propionate 100 µg and
           salmeterol xinafoate 50 µg inhalation powder to placebo.

        -  To demonstrate statistical superiority of Advair 100/50 to placebo.

        -  To investigate the safety and tolerability of fluticasone propionate 100 µg and
           salmeterol xinafoate 50 µg inhalation powder compared with Advair 100/50 in the target
           population.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Baseline-adjusted area under the serial FEV1-time curve from time 0 to 12 hours on the first day of the Treatment Period</measure>
    <time_frame>0-12 hours after dosing on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline-adjusted, pre-dose FEV1 on the last day of the Treatment Period</measure>
    <time_frame>30 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>From Visit 1 (Day -28) until 30 days after the last dose of study drug</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1430</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Fluticasone / Salmeterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Vectura lever operated multidose inhaler (&quot;LOMI&quot;) inhaler device twice a day by inhalation throughout the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Advair Diskus 100/50</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Advair Diskus (fluticasone propionate and salmeterol xinafoate) twice a day by inhalation throughout the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo inhaler</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo inhaled powder twice a day by inhalation throughout the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone / Salmeterol</intervention_name>
    <description>Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Vectura LOMI inhaler device</description>
    <arm_group_label>Fluticasone / Salmeterol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>placebo inhaler</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Advair Diskus 100/50</intervention_name>
    <description>Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate administered via the Diskus inhaler device)</description>
    <arm_group_label>Advair Diskus 100/50</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female subjects must be 12 years of age or older. Females must be of
             non-childbearing potential or if of childbearing potential, must commit to consistent
             use of a form of birth control which is medically effective.

          2. Be able to provide written informed consent or, in the case of adolescents, informed
             assent in addition to an informed consent form signed by the adolescent's parent(s) or
             legal guardian(s).

          3. Be current non-smokers and also may not have used tobacco products (e.g., cigarettes,
             cigars, pipe tobacco) within the year prior to Visit 1, and have 10 years or less (10
             pack-years for cigarettes) of historical use.

          4. Have persistent asthma, as defined by the National Asthma Education and Prevention
             Program, for at least 12 weeks before Visit 1.

          5. The forced expiratory volume at one second (&quot;FEV1&quot;) range required for enrollment is
             dependent on whether the subject is an adult or adolescent and whether he or she is
             currently treated with inhaled corticosteroids (&quot;ICS&quot;) at Visit 1

          6. Demonstrate 15% or greater reversibility of FEV1 between 10 and 30 minutes following
             360 µg of albuterol inhalation. NOTE: If the subject does not meet criterion 6 at
             Visit 1 (Day -14), this criterion must be met at Visit 2 (Day -1).

          7. Be able to discontinue controller asthma medication (including leukotriene modifiers
             (&quot;LTM&quot;), ICS and long acting β-agonists (LABAs)) during the Run-in Period and
             Treatment Period.

          8. Be able to replace current short-acting β-agonists (SABAs) with the study-supplied
             albuterol (or equivalent) rescue medication inhaler for use as needed for the duration
             of the study (subjects should be able to withhold all inhaled SABAs for a least 6
             hours before lung function assessments during study visits).

          9. Be appropriately using 1 of the following asthma-treatment regimens and meet the
             associated criteria:

               -  Low- to medium-dose ICS for at least 4 weeks before Visit 1, with or without an
                  adjunctive asthma therapy (i.e., LABA, LTM, or theophylline). Both the ICS dose
                  and overall daily asthma regimen must have been stable for the 4 weeks before
                  Visit 1; or

               -  Leukotriene modifier (such as montelukast, zafirlukast, or pranlukast) or
                  theophylline as monotherapy at a stable dose for at least 4 weeks before Visit
                  1;or

               -  Daily (or near daily) rescue medication (e.g., albuterol/ salbutamol or other
                  inhaled SABA used to treat acute asthma) in the 4 weeks before Visit 1.

         10. Must not have been treated (for any reason) with oral or parenteral corticosteroids
             for at least 1 month before Visit 1 and must not have used oral SABAs for at least 12
             hours before Visit 1 and for the remainder of the study. Routine use of
             oral/parenteral corticosteroids and oral SABAs is not allowed after Visit 1.

         11. Subjects may continue using short-acting forms of theophylline (withheld at least 12
             hours before a site visit), twice daily controlled release forms of theophylline
             (withheld at least 24 hours before a site visit), and once daily controlled-release
             forms of theophylline (withheld at least 36 hours before a site visit).

         12. Be able to answer questions regarding asthma status and be able to document) device
             usage and asthma status on a twice daily basis.

             NOTE: Placebo inhaler use (i.e., compliance) must be at least 75% of the planned doses
             taken as assessed at Visit 2, for the subject to be considered eligible to continue in
             the study.

         13. Demonstrate proper use of metered dose inhaler (&quot;MDI&quot;) and dry-powder inhaler devices.

        Exclusion Criteria:

          1. Have an Asthma Control Questionnaire (ACQ) score of 3.0 or greater at Visit 1.

          2. Are unable to discontinue ICS, LABA, or LTM.

          3. Have a history of life-threatening asthma, defined as an asthma episode (at any time
             in the past) associated with any of the following: respiratory arrest or intubation,
             hypercapnia, hypoxic seizures, or syncopal episode.

          4. Have exercise-induced asthma as the only asthma-related diagnosis that does not
             require daily asthma control medicine.

          5. Have evidence or history of clinically significant disease or abnormality including
             congestive heart failure, uncontrolled hypertension, uncontrolled coronary artery
             disease, myocardial infarction, or cardiac dysrhythmia. In addition, historical or
             current evidence of significant hematologic, hepatic, neurologic, psychiatric, renal,
             or other diseases that in the opinion of the investigator, would put the subject at
             risk through study participation, or would affect the study analyses if the disease
             exacerbated during the study.

          6. Have current clinical evidence of pneumonia, pneumothorax, atelectasis, pulmonary
             fibrotic disease, allergic bronchopulmonary aspergillosis, cystic fibrosis,
             bronchopulmonary dysplasia, chronic obstructive pulmonary disease, or other
             respiratory abnormalities other than asthma.

          7. Have obstructive sleep apnea severe enough to require biphasic or continuous
             positive-airway pressure therapy, or likely to interfere with the assessment of asthma
             symptoms, in the investigator's judgment.

          8. Using medication with the potential to affect the course of asthma or interact with
             sympathomimetic amines (e.g., β blockers [including eye drops], oral decongestants,
             benzodiazepines, digitalis, phenothiazines, polycyclic antidepressants, monoamine
             oxidase inhibitors).

          9. Had a viral or bacterial, upper or lower respiratory tract infection or sinus or
             middle ear infection within 4 weeks before Visit 1 or have an infection during the
             Run-in Period.

         10. Participated in an interventional study or used any investigational drug for any
             disease within 30 days (or 4 half lives, if this is longer than 30 days) before Visit
             1 before Visit 1.

         11. Used an anti-immunoglobulin E (e.g., omalizumab) or any other monoclonal antibody for
             any reason within 6 months before Visit 1.

         12. Are hypersensitive to any β2-agonist sympathomimetic drug, or any intranasal, inhaled,
             or systemic corticosteroid therapy or any component of these combination medications
             including severe milk protein hypersensitivity.

         13. Are exhibiting any factors (e.g., infirmity, disability, or geographic location,
             inability to follow instructions or study compliance requirements) that the
             investigator believes would likely limit the subject's compliance with the study
             protocol or scheduled site visits. This includes recent history of substance abuse or
             uncontrolled psychiatric or neurological behavior that would render the subject
             incapable of reliably following study requirements, in the judgment of the
             investigator.

         14. Have an affiliation with the participating site; in other words, subject may not be an
             immediate family member of any study site staff and may not be employed directly or
             indirectly by the study site.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #30</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #46</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #1</name>
      <address>
        <city>Surprise</city>
        <state>Arizona</state>
        <zip>85374</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #13</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #84</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #72</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #67</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #4</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>90708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #64</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #3</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #70</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #92</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #38</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #91</name>
      <address>
        <city>Lincoln</city>
        <state>California</state>
        <zip>95648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #59</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #16</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #90</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #6</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #78</name>
      <address>
        <city>Rolling Hills Estates</city>
        <state>California</state>
        <zip>90274</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #98</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95821</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #53</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #93</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #28</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #60</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #33</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #43</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #63</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #21</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <zip>80033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #50</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #11</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #66</name>
      <address>
        <city>Homestead</city>
        <state>Florida</state>
        <zip>33030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #83</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #8</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #23</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #86</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #89</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #20</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #68</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33165</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #80</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #54</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #12</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33185</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #74</name>
      <address>
        <city>North Miami Beach</city>
        <state>Florida</state>
        <zip>33162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #35</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #17</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #94</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #34</name>
      <address>
        <city>Lilburn</city>
        <state>Georgia</state>
        <zip>30047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #51</name>
      <address>
        <city>Rincon</city>
        <state>Georgia</state>
        <zip>31326</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #79</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #47</name>
      <address>
        <city>River Forest</city>
        <state>Illinois</state>
        <zip>60305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #100</name>
      <address>
        <city>Brownsburg</city>
        <state>Indiana</state>
        <zip>46112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #62</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #52</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #71</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #96</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #81</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #56</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #55</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #97</name>
      <address>
        <city>Chelsea</city>
        <state>Michigan</state>
        <zip>48118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #5</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55441</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #85</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #32</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <zip>68005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #25</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <zip>68123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #36</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #57</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #10</name>
      <address>
        <city>Atco</city>
        <state>New Jersey</state>
        <zip>08004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #65</name>
      <address>
        <city>Skillman</city>
        <state>New Jersey</state>
        <zip>08558</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #7</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #2</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #41</name>
      <address>
        <city>Clemmons</city>
        <state>North Carolina</state>
        <zip>27012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #45</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #31</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #95</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #24</name>
      <address>
        <city>Hilliard</city>
        <state>Ohio</state>
        <zip>43026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #61</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #73</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #14</name>
      <address>
        <city>Edmond</city>
        <state>Oklahoma</state>
        <zip>73034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #15</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #37</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #40</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #58</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #26</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #99</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #69</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #22</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #19</name>
      <address>
        <city>Smyrna</city>
        <state>Tennessee</state>
        <zip>37167</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #27</name>
      <address>
        <city>Boerne</city>
        <state>Texas</state>
        <zip>78006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #75</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #49</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #44</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #77</name>
      <address>
        <city>Lewisville</city>
        <state>Texas</state>
        <zip>75067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #87</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #29</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #48</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #42</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #39</name>
      <address>
        <city>South Burlington</city>
        <state>Vermont</state>
        <zip>05403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #9</name>
      <address>
        <city>Henrico</city>
        <state>Virginia</state>
        <zip>23233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #88</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #18</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #76</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roxane Laboratories Research Site #82</name>
      <address>
        <city>Greenfield</city>
        <state>Wisconsin</state>
        <zip>53228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2016</study_first_submitted>
  <study_first_submitted_qc>January 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2016</study_first_posted>
  <last_update_submitted>January 19, 2018</last_update_submitted>
  <last_update_submitted_qc>January 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
    <mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

